TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. DENMARK PHARMACEUTICAL MARKET, BY THERAPEUTIC CLASS
6.1. Overview
6.2. Alimentary Tract and Metabolism
6.3. Blood and Blood Forming Organs
6.4. Cardiovascular System
6.5. Dermatological Drugs
6.6. Genitourinary System
6.7. Reproductive Hormones
6.8. Systemic Hormonal Preparations
6.9. Immunomodulating Agents
6.10. Musculoskeletal System
6.11. Nervous System
6.12. Anti-parasitic Products
6.13. Insecticides and Repellents
6.14. Respiratory System
6.15. Sensory Organs
6.16. Various ATC Structures
7. DENMARK PHARMACEUTICAL MARKET, BY SECTOR
7.1. Overview
7.2. Primary Sector
7.3. Hospital Sector
8. DENMARK PHARMACEUTICAL MARKET, BY PRESCRIPTION TYPE
8.1. Overview
8.2. Prescription Drugs (Rx)
8.3. OTC Drugs
9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Denmark Pharmaceutical Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Denmark Pharmaceutical Market,
9.7. Key Developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger &Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2022
9.8.2. Major Players R&D Expenditure.2022
10. COMPANY PROFILES
10.1. Novo Nordisk A/S
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. H. Lundbeck A/S
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Leo Pharma A/S
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Orifarm Group A/S
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. ALK-Abell A/S
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Xellia ApS
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Takeda Pharma A/S
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Sandoz A/S
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Ferring Pharmaceuticals A/S
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. FUJIFILM Diosynth
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 DENMARK PHARMACEUTICAL MARKET, SYNOPSIS, 2018-2032
TABLE 2 DENMARK PHARMACEUTICAL MARKET, ESTIMATES & FORECAST, 2018-2032(USD BILLION)
TABLE 3 DENMARK PHARMACEUTICAL MARKET, BY THERAPEUTIC CLASS, 2018-2032 (USD BILLION)
TABLE 4 DENMARK PHARMACEUTICAL MARKET, BY SECTOR, 2018-2032 (USD BILLION)
TABLE 5 DENMARK PHARMACEUTICAL MARKET, BY PRESCRIPTION TYPE , 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE DENMARK PHARMACEUTICAL MARKET
FIGURE 3 MARKET DYNAMICS FOR THE DENMARK PHARMACEUTICAL MARKET
FIGURE 4 DENMARK PHARMACEUTICAL MARKET, SHARE (%), BY THERAPEUTIC CLASS, 2022
FIGURE 5 DENMARK PHARMACEUTICAL MARKET, SHARE (%), BY SECTOR, 2022
FIGURE 6 DENMARK PHARMACEUTICAL MARKET, SHARE (%), BY PRESCRIPTION TYPE , 2022
FIGURE 7 DENMARK PHARMACEUTICAL MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 8 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 9 NOVO NORDISK A/S: SWOT ANALYSIS
FIGURE 10 H. LUNDBECK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 11 H. LUNDBECK A/S: SWOT ANALYSIS
FIGURE 12 LEO PHARMA A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 LEO PHARMA A/S: SWOT ANALYSIS
FIGURE 14 ORIFARM GROUP A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ORIFARM GROUP A/S: SWOT ANALYSIS
FIGURE 16 ALK-ABELL A/S.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 ALK-ABELL A/S.: SWOT ANALYSIS
FIGURE 18 XELLIA APS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 XELLIA APS: SWOT ANALYSIS
FIGURE 20 TAKEDA PHARMA A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 TAKEDA PHARMA A/S: SWOT ANALYSIS
FIGURE 22 SANDOZ A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 SANDOZ A/S: SWOT ANALYSIS
FIGURE 24 FERRING PHARMACEUTICALS A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 FERRING PHARMACEUTICALS A/S: SWOT ANALYSIS
FIGURE 26 FUJIFILM DIOSYNTH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 FUJIFILM DIOSYNTH: SWOT ANALYSIS
